Substantial reduction in losses
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
Income declines marginally
It’s an AB-rated generic therapeutic version of Durezol
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
